Who are CINRYZE 500's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): CINRYZE 1000 U, CINRYZE 500 U.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cinryze-500.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

CINRYZE 500 — Competitive Intelligence Brief

CINRYZE 500 (CINRYZE 500) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: C1 esterase inhibitor (C1-INH) replacement therapy. Area: Immunology / Rare Genetic Disorders.

phase 3 C1 esterase inhibitor (C1-INH) replacement therapy C1 esterase inhibitor (C1-INH); contact system/kallikrein-kinin pathway Immunology / Rare Genetic Disorders Biologic Live · refreshed every 30 min

Target snapshot

CINRYZE 500 (CINRYZE 500) — Shire. CINRYZE is a C1 esterase inhibitor (C1-INH) that suppresses activation of the contact system to prevent bradykinin-mediated angioedema attacks.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CINRYZE 500 TARGET	CINRYZE 500	Shire	phase 3	C1 esterase inhibitor (C1-INH) replacement therapy	C1 esterase inhibitor (C1-INH); contact system/kallikrein-kinin pathway
CINRYZE 1000 U	CINRYZE 1000 U	Shire	phase 3	C1 esterase inhibitor (C1-INH) replacement therapy	C1 esterase inhibitor (C1-INH); contact system cascade (Factor XII, kallikrein pathway)
CINRYZE 500 U	CINRYZE 500 U	Shire	phase 3	C1 esterase inhibitor (C1-INH) replacement therapy	C1 esterase inhibitor (C1-INH); contact system cascade regulation

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (C1 esterase inhibitor (C1-INH) replacement therapy class)

Shire · 3 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CINRYZE 500 — Competitive Intelligence Brief. https://druglandscape.com/ci/cinryze-500. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab